OR WAIT null SECS
February 13, 2023
The BLA includes a comprehensive analytical and clinical data package, including data from the Phase I/III ROSALIA study.
February 07, 2023
The COVID-19 pandemic has led to many changes and shifts in the pharmaceutical industry, specifically with how pharmaceutical companies develop vaccines.
February 03, 2023
Topical eye treatments can be beneficial for patients with a growing array of eye diseases, but only if taken appropriately.
Efforts to optimize the delivery of sensitive biotherapeutics continue to evolve.
February 02, 2023
This new pioneering phase of mRNA is loaded with potential, but also obstacles and false dawns.
January 30, 2023
FDA plans to authorize a common bivalent shot that targets both the original COVID-19 strain and Omicron subvariants.
January 16, 2023
The members reviewed the measures to minimize the risk of serious side effects associated with Janus kinase (JAK) inhibitors used to treat several chronic inflammatory disorders.
January 03, 2023
Bio/pharma has evolved and adapted to a variety of challenges in 2022, but what might be on the cards for the industry in 2023?
Inhaled vaccines must resist degradation and penetrate the mucosal lining in the airways and lungs.